Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2-metastatic breast cancer (mBC)

被引：0
|
作者：
Avesani, Barbara
Giontella, Elena
Caldart, Alberto
De Noni, Alessandro
Muzzarelli, Alice
Borghesani, Giulia
Insolda, Jessica
Biondani, Pamela
Parolin, Veronica
Pellini, Francesca
Scarpa, Aldo
Nottegar, Alessia
Lawlor, Rita T.
Mafficini, Andrea
Paris, Ida
Minucci, Angelo
Pasciuto, Tina
Fabi, Alessandra
Fiorio, Elena
Milella, Michele
机构：
[1] Azienda Osped Univ Integrata Verona, Med Oncol, Verona, Italy
[2] Azienda Osped Univ Integrata Verona, Verona, Italy
[3] Azienda Osped Univ Integrata Verona, Sect Breast Surg, Verona, Italy
[4] Univ Verona, Sect Pathol, Dept Diagnost & Publ Hlth, Verona, Italy
[5] Hosp Trust Verona, Verona, Italy
[6] Univ Verona, Sect Pathol, Verona, Italy
[7] ARC NET, Verona, Italy
[8] Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[9] Univ Cattolica Sacro Cuore, Dept Unit Mol & Genom Diagnost, Fdn Policlin Univ Agostino Gemelli IRCCS, Rome, Italy
[10] Univ Cattolica Sacro Cuore, Policlin Agostino Gemelli, Rome, Italy
[11] IRCCS, Precis Med Senol, Fdn Policlin Univ Agostino Gemelli, Rome, Italy
[12] Univ Verona Hosp Trust, Dept Oncol, Verona, Italy
[13] Univ Verona, Sch Med, Sect Oncol, Verona, Italy
[14] Verona Univ Hosp Trust, Verona, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13079
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Breast cancer specific survival (BCSS) in HR+/HER2-metastatic breast cancer (mBC) from 2010 to 2019
    Brufsky, A. M.
    Kwan, M.
    Sandin, R.
    Karanth, S.
    Cha-Silva, A.
    Makari, D.
    Stergiopoulos, S.
    Goyal, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S351 - S352
  • [2] Abemaciclib in HR+/HER2-metastatic breast cancer: A realworld experience
    Bottosso, M.
    Giarratano, T.
    Barbieri, C.
    Menichetti, A.
    Cumerlato, E.
    Miglietta, F.
    Genovesi, E.
    Amato, O.
    Dieci, M. V.
    Griguolo, G.
    Guarneri, V.
    ANNALS OF ONCOLOGY, 2021, 32 : S73 - S74
  • [3] Everolimus-based combination therapies for HR+, HER2-metastatic breast cancer
    O'Shaughnessy, Joyce
    Beck, J. Thaddeus
    Royce, Melanie
    CANCER TREATMENT REVIEWS, 2018, 69 : 204 - 214
  • [4] Experience with eribulin in HR+/HER2-metastatic breast cancer, including a male
    Munoz Sanchez, Maria del Mar
    Soriano Rodriguez, Maria del Carmen
    Molina Garrido, Maria Jose
    Lopez-Gonzalez, Ana
    Garcia-Palomo, Andres
    Lopez-Gonzalez, Laura
    Plata Fernandez, Maria Yessica
    Luque Caro, Natalia
    Sanchez Rovira, Pedro
    FUTURE ONCOLOGY, 2018, 14 (07) : 5 - 12
  • [5] Sacituzumab govitecan in HR+ and HER2-metastatic breast cancer: for all or for some?
    Loibl, Sibylle
    Holtschmidt, Johannes
    LANCET, 2023, 402 (10411): : 1394 - 1395
  • [6] Physician survey in the treatment of HR+/HER2-metastatic breast cancer in Egypt
    Aboelkheir, E.
    Ashour, A.
    Fadel, S.
    Arafat, W.
    BREAST, 2021, 56 : S31 - S31
  • [7] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [8] VALIDATION OF AN ALGORITHM TO IDENTIFY HR+/HER2-METASTATIC BREAST CANCER IN CLAIMS DATA
    Chin, A.
    Ip, Q.
    Wu, X.
    Lyle, D.
    VALUE IN HEALTH, 2024, 27 (06) : S163 - S163
  • [9] Cost of recurrence among patients with HR+/HER2-metastatic breast cancer.
    Engel-Nitz, Nicole M.
    Becker, Laura
    Gerdes, Randall
    Hao, Yanni
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] A Phase 2 Study of Abemaciclib in Patients (PTS) with Brain Metastases (BM) Secondary to HR+, HER2-Metastatic Breast Cancer (MBC)
    Anders, Carey
    Le Rhun, Emily
    Bachelot, Thomas
    Yardley, Denise
    Awade, Ahmad
    Conte, Pierre Franco
    Cabos, Peter
    Bear, Melissa
    Tolaney, Sarah
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 10 - 10
12345